Puma Biotechnology (0PB) Q3 2026 Earnings Report

The call was broadly positive. Management reported year-over-year U.S. NERLYNX demand growth, higher net product revenue, increased full-year net income guidance, strong cash generation, a debt-free balance sheet, and continued progress in the alisertib pipeline. These positives were partly offset by lower quarter-over-quarter bottle sales and U.S. net sales, declines in several commercial activity metrics, lower royalty revenue due in part to the China generic threshold, higher gross-to-net adjustments, and increased expected R&D spending.

For fiscal year 2026, Puma anticipates net NERLYNX product revenue in the range of $205 million-$208 million, a gross-to-net adjustment between 27.5% and 28%, royalties from partners around the world in the range of $18 million-$19 million, no license revenue, and net income in the range of $20 million-$22 million; for Q4 2026, it anticipates NERLYNX product revenue net in the range of $56 million-$58 million, Q4 royalties revenues in the range of $11 million-$12 million, no license revenue, a gross-to-net adjustment of approximately 28%-29%, and net income between $10 million and $12 million. Puma anticipates SG&A expenses to remain flat and R&D expenses to increase by 28%-30% year-over-year, expects to recognize amortization of milestones to the licensor of about $2.4 million per quarter as cost of sales, and does not believe tariffs imposed or proposed to be imposed by the U.S., particularly with other countries, will have a material impact on product cost or results of operation.